Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total Stockholder's Equity [Member]	Common Stock	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Deferred Compensation [Member]	Noncontrolling Interests [Member]	Series B Preferred Stock	Total
Beginning Balance at Oct. 31, 2020		$ 29	$ 1,359,454	$ (1,164,196)	$ (739)	$ (432)	$ 432			$ 194,548
Beginning Balance at (in shares) at Oct. 31, 2020		294,706,758
Sale of common stock, net of fees		$ 3	156,363							156,366
Sale of common stock, net of fees (in shares)		25,000,000
Orion warrant exercises			21,824							21,824
Orion warrant exercises (in shares)		2,700,000
Common stock issued, non-employee compensation			45							45
Common stock issued, non-employee compensation (in shares)		2,734
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards			8							8
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)		4,521
Share based compensation			1,417							1,417
Preferred dividends - Series B			(800)							(800)
Effect of foreign currency translation					58					58
Adjustment for deferred compensation						(30)	30
Adjustment for deferred compensation (in shares)		(1,669)
Release of a share reserve		(48)
Net Loss				(45,960)						(45,960)
Ending Balance at Jan. 31, 2021		$ 32	1,538,311	(1,210,156)	(681)	(462)	462			327,506
Ending Balance at (in shares) at Jan. 31, 2021		322,412,296
Beginning Balance at Oct. 31, 2020		$ 29	1,359,454	(1,164,196)	(739)	(432)	432			194,548
Beginning Balance at (in shares) at Oct. 31, 2020		294,706,758
Preferred dividends - Series B									$ (2,400)
Effect of foreign currency translation										(8)
Net Loss										(76,874)
Ending Balance at Jul. 31, 2021		$ 37	1,908,011	(1,241,070)	(747)	(544)	544			666,231
Ending Balance at (in shares) at Jul. 31, 2021		366,483,758
Beginning Balance at Jan. 31, 2021		$ 32	1,538,311	(1,210,156)	(681)	(462)	462			327,506
Beginning Balance at (in shares) at Jan. 31, 2021		322,412,296
Sale of common stock, net of fees			5							5
Orion warrant exercises			269							269
Orion warrant exercises (in shares)		14,026
Common stock issued, non-employee compensation			55							55
Common stock issued, non-employee compensation (in shares)		5,456
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards			(262)							(262)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)		64,782
Share based compensation			1,253							1,253
Preferred dividends - Series B			(800)							(800)
Effect of foreign currency translation					(60)					(60)
Adjustment for deferred compensation						(41)	41
Adjustment for deferred compensation (in shares)		(3,756)
Net Loss				(18,917)						(18,917)
Ending Balance at Apr. 30, 2021		$ 32	1,538,831	(1,229,073)	(741)	(503)	503			309,049
Ending Balance at (in shares) at Apr. 30, 2021		322,492,804
Sale of common stock, net of fees		$ 5	368,949							368,954
Sale of common stock, net of fees (in shares)		43,978,999
Common stock issued, non-employee compensation			95							95
Common stock issued, non-employee compensation (in shares)		12,985
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards			33							33
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)		4,828
Share based compensation			903							903
Preferred dividends - Series B			(800)						(800)	(800)
Effect of foreign currency translation					(6)					(6)
Adjustment for deferred compensation						(41)	41
Adjustment for deferred compensation (in shares)		(5,858)
Net Loss				(11,997)						(11,997)
Ending Balance at Jul. 31, 2021		$ 37	1,908,011	(1,241,070)	(747)	(544)	544			666,231
Ending Balance at (in shares) at Jul. 31, 2021		366,483,758
Beginning Balance at Oct. 31, 2021	$ 642,438	$ 37	1,908,471	(1,265,251)	(819)	(586)	586			$ 642,438
Beginning Balance at (in shares) at Oct. 31, 2021		366,618,693								366,618,693
Common stock issued, non-employee compensation	100		100							$ 100
Common stock issued, non-employee compensation (in shares)		20,673
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards	(260)		(260)							(260)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)		60,052
Share based compensation	1,470		1,470							1,470
Preferred dividends - Series B	(800)		(800)							(800)
Effect of foreign currency translation	(91)				(91)					(91)
Adjustment for deferred compensation						(64)	64
Adjustment for deferred compensation (in shares)		(13,232)
Net income (loss) attributable to noncontrolling interest	5,496			5,496				$ (5,496)
Net Loss	(46,120)			(46,120)						(46,120)
Ending Balance at Jan. 31, 2022	602,233	$ 37	1,908,981	(1,305,875)	(910)	(650)	650	(5,496)		596,737
Ending Balance at (in shares) at Jan. 31, 2022		366,686,186
Beginning Balance at Oct. 31, 2021	642,438	$ 37	1,908,471	(1,265,251)	(819)	(586)	586			$ 642,438
Beginning Balance at (in shares) at Oct. 31, 2021		366,618,693								366,618,693
Preferred dividends - Series B									(2,400)
Effect of foreign currency translation										$ (326)
Net income (loss) attributable to noncontrolling interest										4,968
Net Loss										(105,223)
Ending Balance at Jul. 31, 2022	690,014	$ 39	2,056,626	(1,365,506)	(1,145)	(786)	786	6,766		$ 696,780
Ending Balance at (in shares) at Jul. 31, 2022		394,430,969								394,430,969
Beginning Balance at Jan. 31, 2022	602,233	$ 37	1,908,981	(1,305,875)	(910)	(650)	650	(5,496)		$ 596,737
Beginning Balance at (in shares) at Jan. 31, 2022		366,686,186
Sale of common stock, net of fees	118,264	$ 2	118,262							118,264
Sale of common stock, net of fees (in shares)		19,896,904
Common stock issued, non-employee compensation	68		68							68
Common stock issued, non-employee compensation (in shares)		13,002
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)		25,779
Share based compensation	1,695		1,695							1,695
Preferred dividends - Series B	(800)		(800)							(800)
Effect of foreign currency translation	(149)				(149)					(149)
Adjustment for deferred compensation						(68)	68
Adjustment for deferred compensation (in shares)		(13,002)
Reclassification of noncontrolling interest								12,419		12,419
Return of capital to noncontrolling interest								(496)		(496)
Distribution to noncontrolling interest								(95)		(95)
Net income (loss) attributable to noncontrolling interest	(91)			(91)				91
Net Loss	(30,126)			(30,126)						(30,126)
Ending Balance at Apr. 30, 2022	691,094	$ 39	2,028,206	(1,336,092)	(1,059)	(718)	718	6,423		697,517
Ending Balance at (in shares) at Apr. 30, 2022		386,608,869
Sale of common stock, net of fees	27,173		27,173							27,173
Sale of common stock, net of fees (in shares)		7,814,115
Common stock issued, non-employee compensation	68		68							68
Common stock issued, non-employee compensation (in shares)		19,594
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards	18		18							18
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)		7,985
Share based compensation	1,961		1,961							1,961
Preferred dividends - Series B	(800)		(800)						$ (800)	(800)
Effect of foreign currency translation	(86)				(86)					(86)
Adjustment for deferred compensation						(68)	68
Adjustment for deferred compensation (in shares)		(19,594)
Distribution to noncontrolling interest								(94)		(94)
Net income (loss) attributable to noncontrolling interest	(437)			(437)				437		(437)
Net Loss	(28,977)			(28,977)						(28,977)
Ending Balance at Jul. 31, 2022	$ 690,014	$ 39	$ 2,056,626	$ (1,365,506)	$ (1,145)	$ (786)	$ 786	$ 6,766		$ 696,780
Ending Balance at (in shares) at Jul. 31, 2022		394,430,969								394,430,969